The National Markets and Competition Commission upholds the legality of the free price policies applied by several pharmaceutical companies in Spain

In a resolution passed on 30 August 2018 (File S/DC/0608/17, EAEPC vs Pharmaceutical Companies - the “Resolution”), the National Markets and Competition Commission brought to an end the infringement proceedings initiated against six multinational pharmaceutical companies (Pfizer, Lilly, Janssen-Cilag, Novartis, Sanofi and MSD) for alleged practices prohibited by article 1 of the Spanish Competition Law and by Article 101 of the Treaty on the Functioning of the European Union. The practices in question mainly consisted of setting up an alleged dual-pricing system for their medicines, depending on whether they were dispensed in Spain or intended for intra-community trade or export.

For more information, please follow the link.

For further information, please contact:

Pilar Igartua
Uría Menéndez Madrid
Tel: +34 91 586 03 72